Where available, links to recent updates published by national public health authorities in the EU/EEA can be found in the CDTR [3].

Figure 1. Number of measles cases by country, EU/EEA, August 2019 ( $\mathrm{n}=453$ )
Number of measles cases, August 2019

- 0
- 1
- 10

100EU/EEA Member States
Other countries


## Measles cases from September 2018-August 2019

From 1 September 2018-31 August 2019, 30 EU/EEA Member States reported 13264 cases of measles, 10507 ( $79 \%$ ) of which were laboratory confirmed. No countries reported zero cases during the 12 -month period. The highest number of cases were reported by France (2675), Italy (1847), Poland (1582), Romania (1445) and Bulgaria ( 1158 ), accounting for $20 \%, 14 \%, 12 \%, 11 \%$ and $9 \%$ of all cases, respectively (Table 1). Notification rates per million population above the EU/EEA average of 25.6 were reported by Lithuania (303.0), Bulgaria (164.2), Slovakia (82.3), Romania (74.0), Malta (65.2), the Czech Republic (59.5), Poland (41.7), Luxembourg (41.5), France (40.0), Belgium (38.6) and Italy (30.5); (Figure 2).

The number of measles cases reported to TESSy may be an underestimation in certain countries. This may apply in particular to Romania. The sustained outbreak in the country has caused delays in case-based reporting to TESSy and the most up-to-date data are available from the Romanian National Institute of Public Health [5].
Table 1. Number of measles cases by month and notification rate per million population by country, EU/EEA, 1 September 2018-31 August 2019

|  | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Country | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Total cases | Cases per million | Total labpositive cases |
| Austria | 6 | 0 | 4 | 1 | 25 | 33 | 1 | 27 | 38 | 8 | 4 | 7 | 154 | 17.5 | 143 |
| Belgium | 14 | 4 | 6 | 6 | 20 | 87 | 67 | 34 | 94 | 66 | 28 | 14 | 440 | 38.6 | 341 |
| Bulgaria | 0 | 0 | 0 | 0 | 0 | 51 | 185 | 279 | 281 | 236 | 84 | 42 | 1158 | 164.2 | 1047 |
| Croatia | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 6 | 10 | 4 | 25 | 6.1 | 25 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 0 | 0 | 6 | 6.9 | 5 |
| Czech Republic | 4 | 7 | 16 | 19 | 58 | 150 | 199 | 90 | 50 | 20 | 14 | 4 | 631 | 59.5 | 551 |
| Denmark | 2 | 0 | 0 | 1 | 2 | 5 | 4 | 2 | 1 | 1 | 0 | 0 | 18 | 3.1 | 18 |
| Estonia | 0 | 0 | 0 | 0 | 3 | 6 | 2 | 0 | 6 | 7 | 1 | 1 | 26 | 19.7 | 25 |


|  | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Country | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Total cases | Cases per million | Total labpositive cases |
| Finland | 0 | 0 | 1 | 7 | 3 | 3 | 0 | 2 | 0 | 0 | 0 | 0 | 16 | 2.9 | 16 |
| France | 38 | 76 | 62 | 61 | 122 | 209 | 321 | 341 | 557 | 467 | 314 | 107 | 2675 | 40.0 | 1625 |
| Germany | 24 | 13 | 10 | 10 | 102 | 71 | 129 | 70 | 50 | 20 | 20 | 19 | 538 | 6.5 | 426 |
| Greece | 4 | 2 | 0 | 1 | 0 | 3 | 7 | 12 | 6 | 0 | 0 | 0 | 35 | 3.3 | 20 |
| Hungary | 0 | 0 | 0 | 1 | 2 | 5 | 4 | 2 | 9 | 0 | 1 | 0 | 24 | 2.5 | 24 |
| Iceland | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 0 | 0 | 0 | 1 | 0 | 8 | 23.0 | 8 |
| Ireland | 2 | 1 | 1 | 0 | 2 | 18 | 23 | 6 | 10 | 2 | 3 | 1 | 69 | 14.3 | 36 |
| Italy | 57 | 82 | 58 | 76 | 180 | 173 | 229 | 309 | 237 | 217 | 152 | 77 | 1847 | 30.5 | 1544 |
| Latvia | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | . | 4 | 2.1 | 4 |
| Lithuania | 0 | 0 | 8 | 20 | 12 | 73 | 250 | 232 | 122 | 62 | 32 | 40 | 851 | 303.0 | 851 |
| Luxembourg | 0 | 0 | 1 | 0 | 0 | 0 | 15 | 7 | 1 | 1 | 0 | 0 | 25 | 41.5 | 25 |
| Malta | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 13 | 11 | 3 | 0 | 1 | 31 | 65.2 | 31 |
| Netherlands | 0 | 0 | 0 | 2 | 4 | 4 | 10 | 2 | 13 | 16 | 9 | 9 | 69 | 4.0 | 60 |
| Norway | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 3 | 3 | 1 | 0 | 2 | 17 | 3.2 | 14 |
| Poland | 9 | 21 | 79 | 114 | 164 | 239 | 287 | 256 | 244 | 122 | 40 | 7 | 1582 | 41.7 | 1056 |
| Portugal | 3 | 2 | 24 | 12 | 2 | 2 | 2 | 0 | 2 | 1 | 0 | 0 | 50 | 4.9 | 47 |
| Romania | 72 | 65 | 81 | 130 | 261 | 77 | 188 | 110 | 148 | 123 | 110 | 80 | 1445 | 74.0 | 1135 |
| Slovakia | 28 | 16 | 38 | 50 | 43 | 37 | 70 | 105 | 43 | 9 | 3 | 6 | 448 | 82.3 | 385 |
| Slovenia | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 6 | 8 | 3 | 1 | 1 | 20 | 9.7 | 20 |
| Spain | 4 | 4 | 1 | 6 | 11 | 11 | 23 | 67 | 74 | 28 | 13 | 11 | 253 | 5.4 | 230 |
| Sweden | 4 | 1 | 0 | 3 | 0 | 1 | 4 | 6 | 4 | 2 | 2 | 0 | 27 | 2.7 | 24 |
| United Kingdom | 16 | 21 | 26 | 11 | 81 | 81 | 108 | 118 | 125 | 113 | 52 | 20 | 772 | 11.7 | 771 |
| EU/EEA | 287 | 316 | 417 | 533 | 1097 | 1343 | 2144 | 2101 | 2144 | 1535 | 894 | 453 | 13264 | 25.6 | 10507 |

Source: TESSy, data extracted on 30 September 2019
.: data not reported.
Figure 2. Measles notification rate per million population by country, EU/EEA, 1 September 201831 August 2019

Notification rate of measles (per million), September 2018-August 2019



Thirteen deaths attributable to measles were reported to TESSy during the 12-month period in Romania (5), France (3), Italy (3), Hungary (1) and United Kingdom (1); (Figure 3).

Figure 3. Number of measles deaths by country, EU/EEA, 1 September 2018-31 August 2019 ( $\mathrm{n}=13$ )
Number of measles deaths, September 2018-August 2019

- 0
- $\quad 1$
- 10
EU/EEA Member States
$\square$ Other countries


Importation status was reported by 30 countries and known for 10067 cases ( $76 \%$ ), 905 ( $9 \%$ ) of which were imported and 312 (3\%) of which were import related (see notes).
Of the 12594 cases with known age, 3608 (29\%) were children under five years, and 6960 (55\%) were aged 15 years or older. The highest notification rates were observed in infants under one year ( 281.7 cases per million) and aged 1-4 years ( 103.8 cases per million).
A total of 3005 cases ( $23 \%$ ) had unknown vaccination status. The proportion of cases with unknown vaccination status was highest in adults aged 30 years and above ( 1622 of 4047 cases; $40 \%$ ). Of 9589 cases ( $72 \%$ of all cases) with known age and vaccination status, 6767 ( $71 \%$ ) were unvaccinated, 1694 ( $18 \%$ ) were vaccinated with one dose of a measles-containing vaccine, 956 (10\%) were vaccinated with two or more doses, and 172 (2\%) were vaccinated with an unknown number of doses.

The proportion of unvaccinated cases was highest among infants under one year (1 237 of 1435 cases; 86\%). Infants under one year are particularly vulnerable to measles complications and are best protected by herd immunity as the first dose of a measles-containing vaccine is given after 12 months of age in most EU/EEA countries [6]. Among 2173 cases aged 1-4 years (the target group of the first, and in certain countries second, dose [6]), 1392 ( $64 \%$ ) were unvaccinated, 461 ( $21 \%$ ) were vaccinated with one dose of a measles-containing vaccine, $29(1 \%)$ were vaccinated with two or more doses and $6(<1 \%)$ were vaccinated with an unknown number of doses.

Measles continues to spread across Europe because vaccination coverage in many countries is suboptimal. Sustained coverage of at least $95 \%$ for two doses of a measles-containing vaccine at all subnational levels is recommended [7]. However, the latest WHO-UNICEF estimates of national immunisation coverage show that only five EU/EEA countries (Hungary, Malta, Portugal, Slovakia and Sweden) reported at least 95\% vaccination coverage for both the first [8] and second [9] doses in 2018 (Figure 4). If the elimination goal is to be reached, many countries need to make sustained improvements in the coverage of their routine childhood immunisation programmes and also close immunity gaps in adolescents and adults who have missed vaccination opportunities in the past [4].

Figure 4. Vaccination coverage for first (left) dose of a measles- and rubella-containing vaccine and second (right) dose of a measles-containing vaccine, EU/EEA, 2018


## Rubella

## Rubella in August 2019

Twenty-seven countries reported rubella data for August 2019: three countries (Germany, Italy and Poland) reported 25 cases, while 24 countries reported no cases (Figure 5).

Overall, case numbers changed little compared with the previous two months. Sixteen of the 25 cases (64\%) were reported by Poland (Table 2).

Latvia did not report rubella data for August 2019. Poland reported aggregate data, while all other countries reported case-based data. Cases classified as discarded (see notes) are not included in the figures presented in the report.

Figure 5. Number of rubella cases by country, EU/EEA, August 2019 ( $\mathbf{n = 2 5}$ )
Number of rubella cases, August 2019

- 0
- 1
- 10

100


## Rubella cases from September 2018-August 2019

From 1 September 2018-31 August 2019, 10 EU/EEA Member States reported 429 cases of rubella, 46 (11\%) of which were laboratory confirmed. Eighteen countries reported no cases during the 12 -month period. The highest number of cases were reported by Poland (322), Germany (62), Italy (19) and Spain (12), accounting for 75\%, $14 \%, 4 \%$ and $3 \%$ of all cases, respectively (Table 2). Notification rates per million population above the EU/EEA average (1.0) were reported by Poland (8.5) and Latvia (1.6); (Figure 6).
Data from Poland should be interpreted with caution, as only four of 322 cases (1\%) were laboratory confirmed. The highest burden among cases reported by Poland was in children, with 91 (28\%) cases in children aged 1-4 years, 90 (28\%) cases in children aged 5-9 years, and 45 (14\%) cases in infants under one year.
No deaths attributable to rubella were reported to TESSy during the 12-month period.
Table 2. Number of rubella cases by month and notification rate per million population by country, EU/EEA, 1 September 2018-31 August 2019

|  | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Country | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Total <br> cases | Cases per <br> million | Total lab- <br> positive <br> cases |
| Austria | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0.2 | 1 |
| Bulgaria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Croatia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Cyprus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Czech Republic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Denmark | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Estonia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Finland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Germany | 6 | 6 | 1 | 4 | 4 | 3 | 7 | 5 | 5 | 5 | 8 | 8 | 62 | 0.8 | 19 |
| Greece | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Hungary | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Iceland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.0 | 0 |
| Ireland | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 3 | 0.6 | 0 |
| Italy | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 0 | 4 | 5 | 0 | 1 | 19 | 0.3 | 8 |


|  | 2018 | 2018 | 2018 | 2018 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 | 2019 |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Country | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | $\begin{array}{c}\text { Total } \\ \text { cases }\end{array}$ |  |
| Cases per |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| million |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \(\left.\begin{array}{l}Total lab- <br>

positive <br>
cases\end{array}\right)\)

Source: TESSy, data extracted on 30 September 2019
.: data not reported.
The national surveillance system for rubella in Denmark currently only captures rubella infections during pregnancy; therefore the true incidence of rubella in the Danish population is underestimated.

Figure 6. Rubella notification rate per million population by country, EU/EEA, 1 September 201831 August 2019

Notification rate of rubella (per million), September 2018-August 2019

Luxembourg

Malta


The latest WHO-UNICEF estimates of national immunisation coverage [10] show that 15 EU/EEA countries reported at least $95 \%$ vaccination coverage for the first dose of a rubella-containing vaccine in 2018 (Figure 4). Sustained vaccination coverage of at least $95 \%$ for at least one dose of a rubella-containing vaccine at all subnational levels is recommended to achieve elimination [7].

## References

1. European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases - Measles [Internet]. Stockholm: ECDC; 2019 [cited 8 October 2019]. Available from:
https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=335
2. European Centre for Disease Prevention and Control. Infographics on measles - Monthly measles infographics [Internet]. Stockholm: ECDC; 2019 [cited 8 October 2019]. Available from: http://ecdc.europa.eu/measles/facts/infographics
3. European Centre for Disease Prevention and Control. Communicable disease threats report, 6-12 October 2019, week 41. Stockholm: ECDC; 2019 Available from http://ecdc.europa.eu/publications-data/communicable-disease-threats-report-6-12-october-2019-week-41
4. European Centre for Disease Prevention and Control. Risk assessment: Who is at risk for measles in the EU/EEA? Identifying susceptible groups to close immunity gaps towards measles elimination - 28 May 2019. Stockholm: ECDC; 2019. Available from https://ecdc.europa.eu/en/publications-data/risk-assessment-measles-eu-eea-2019
5. National Institute of Public Health Romania. Situatia rujeolei in Romania (Measles situation reports in Romania) [Internet]. Bucharest: INSP; 2019 [cited 8 October 2019]. Available from:
http://www.cnscbt.ro/index.php/informari-saptamanale/rujeola-1
6. European Centre for Disease Prevention and Control. Vaccine Scheduler [Internet]. Stockholm: ECDC; 2019 [cited 8 October 2019]. Available from: http://vaccine-schedule.ecdc.europa.eu
7. World Health Organization Regional Office for Europe. Eliminating measles and rubella - Framework for the verification process in the WHO European Region. Copenhagen: WHO Regional Office for Europe; 2014. Available from: http://www.euro.who.int/ data/assets/pdf file/0009/247356/Eliminating-measles-and-rubella-Framework-for-the-verification-process-in-the-WHO-European-Region.pdf
8. World Health Organization. WHO-UNICEF estimates of MCV1 coverage [Internet]. Geneva: WHO; 2019 [cited 3 September 2019]. Available from:
http://apps.who.int/immunization monitoring/qlobalsummary/timeseries/tswucoveragemcv1.html
9. World Health Organization. WHO-UNICEF estimates of MCV2 coverage [Internet]. Geneva: WHO; 2019 [cited 3 September 2019]. Available from:
http://apps.who.int/immunization monitoring/globalsummary/timeseries/tswucoveragemcv2.html
10. World Health Organization. WHO-UNICEF estimates of RCV1 coverage [Internet]. Geneva: WHO; 2019 [cited 3 September 2019]. Available from: http://apps.who.int/immunization monitoring/globalsummary/timeseries/tswucoveragercv1.html

## Notes

TESSy collects a 'date used for statistics', which is a date chosen by the country for reporting purposes. This date may indicate onset of disease, date of diagnosis, date of notification or date of laboratory confirmation, depending on reporting practices in the respective countries. All data presented in this reported are based on the 'date used for statistics'. In addition, when reporting data on measles, rubella and other vaccine-preventable diseases to TESSy, countries may update previously reported data. This means that the date of retrieval can influence the data presented in this report, as later retrievals of data relating to the same period may result in slightly different numbers. The data for this report were retrieved on 30 September 2019.
Cases classified as discarded were suspected cases for whom subsequent investigation revealed a negative laboratory test, or confirmation of an alternative aetiology, supported by epidemiological and/or virological evidence.

Cases were classified as imported if there was virological and/or epidemiological evidence of exposure outside the region or country $7-18$ days prior to rash onset, while cases were classified as import related if they were locally acquired infections caused by imported virus, as supported by epidemiological and/or virological evidence.

